[
  {
    "ts": null,
    "headline": "Biogen Gets EU Nod for First Postpartum Depression Drug",
    "summary": "BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=609993b0572dcb1cfc4850708ee20b9203617428856eb311846813ede9ec0e99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758205020,
      "headline": "Biogen Gets EU Nod for First Postpartum Depression Drug",
      "id": 136799833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=609993b0572dcb1cfc4850708ee20b9203617428856eb311846813ede9ec0e99"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates",
    "summary": "Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx™ has the potential to be a new, convenient way to administer medicines to patients living with neurological disorders. CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therape",
    "url": "https://finnhub.io/api/news?id=b410c9344997b9663e979e58da238c6f6975bc9cd9dbe119204a157b0c6e0340",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758199200,
      "headline": "Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates",
      "id": 136798011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx™ has the potential to be a new, convenient way to administer medicines to patients living with neurological disorders. CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therape",
      "url": "https://finnhub.io/api/news?id=b410c9344997b9663e979e58da238c6f6975bc9cd9dbe119204a157b0c6e0340"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s Zurzuvae approved as first postpartum depression drug in Europe",
    "summary": "The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past two years.",
    "url": "https://finnhub.io/api/news?id=ec3f89815aacb633356c19f68b60eef6c55b6b2ff237fdf9f9d1c67e6b7709ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758198623,
      "headline": "Biogen’s Zurzuvae approved as first postpartum depression drug in Europe",
      "id": 136798012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past two years.",
      "url": "https://finnhub.io/api/news?id=ec3f89815aacb633356c19f68b60eef6c55b6b2ff237fdf9f9d1c67e6b7709ff"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs",
    "summary": "The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.",
    "url": "https://finnhub.io/api/news?id=0c50590bd35425d9b98ed68cb6bebc6331ee8ec99750dbbf3d7b981720360f58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758197220,
      "headline": "Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs",
      "id": 136799834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.",
      "url": "https://finnhub.io/api/news?id=0c50590bd35425d9b98ed68cb6bebc6331ee8ec99750dbbf3d7b981720360f58"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to Buy Alcyone Therapeutics for Initial $85 Million",
    "summary": "Biogen to Buy Alcyone Therapeutics for Initial $85 Million",
    "url": "https://finnhub.io/api/news?id=55591b2cb2bef52cf3fef53009e9fbd119d2822b9f256999e3243bc9a284ccb6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758185940,
      "headline": "Biogen to Buy Alcyone Therapeutics for Initial $85 Million",
      "id": 136813292,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen to Buy Alcyone Therapeutics for Initial $85 Million",
      "url": "https://finnhub.io/api/news?id=55591b2cb2bef52cf3fef53009e9fbd119d2822b9f256999e3243bc9a284ccb6"
    }
  }
]